Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 3, 2015, Pages

  Chen, Der Yuan ^a,b,c   Chen, Yi Ming ^a   Tsai, Wen Chan ^d   Tseng, Jui Cheng ^e   Chen, Yi Hsing ^a   Hsieh, Chia Wei ^a,b   Hung, Wei Ting ^a   Lan, Joung Liang ^f  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DAS28; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESPONSE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RADIOIMMUNOASSAY KIT; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; AGED; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84928111749     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203893     Document Type: Article

References (52)

1. Christodoulou C, Choy EH. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med 2006;6:13-19.
2. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
3. Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003;9:1245-50.
4. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. TEMPO Study Investigators: Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
5. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
6. Kievit W, Fransen J, Adang EMM, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch rheumatoid arthritis monitoring register. Rheumatology (Oxford) 2011;50:196-203.
7. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009;11 (Suppl 1):S1.
8. Alzabin S, Abraham SM, Taher TE, et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis 2012;71:1741-8.
9. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical response in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.
10. van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization. Ann Rheum Dis 2013;72:104-9.
11. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2003;18:1257-9.
12. Anderson P, Louie J, Lau A, et al. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 2005;7:3-9.
13. Svenson BM, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-a biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007;46:1828-34.
14. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-68.
15. Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102.
16. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011;70:284-8.
17. Krieckaert CL, Bartelds GM, Lems WF, et al. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010;12:217.
18. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947-55.
19. Aarden L, Ruuls SR, Wolbink GJ. Immunogenicity of anti-tumor necrosis factor antibodies: toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008;20:431-5.
20. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biological: assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211-15.
21. van Schouwenburg PA, Bartelds GM, Hart MH, et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J lmmunol Methods 2010;362:82-8.
22. Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1445-52.
23. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.
24. Daïen CI, Daïen V, Parussini E, et al. Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study. J Rheumatol 2012;39:1533-8.
25. Jamnitski A, Krieckaert CL, Nurmohamed MT, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71:88-91.
26. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
27. Ledingham J, Deighton C: British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005;44:157-63.
28. Prevoo MLL, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
29. Van Gestel AM, Prevoo ML, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
30. Hart MH, de Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;372:196-203.
31. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:531-5.
32. Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumor necrosis factor (TNF)-specific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.
33. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21.
34. Francisca LT, de Salazar JRG, Gallego JMS, et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med 2012;50:1845-7.
35. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012;71:1914-15.
36. Weinblatt ME, Schiff MH, Ruderman EM, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008;58:1921-30.
37. Hoshino M, Yoshio T, Onishi S, et al. Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2011;22:532-40.
38. Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:238-47.
39. Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
40. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93:2645-68.
41. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79.
42. Krieckaert CL, Jamnitski A, Nurmohamed MT, et al. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012;64:3850-5.
43. van der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007;66:253-6.
44. van schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164-72.
45. Mulleman D, Chu Miow Lin D, Ducourau E, et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit 2010;32:232-6.
46. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, et al. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010;38:82-9.
47. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor inhibitor Infliximab. Arthritis Rheum 2006;54:3782-9.
48. Garcês S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumor necrosis factor inhibitor therapies. Ann Rheum Dis 2013. Published Online First: 11 May 2013. 10.1136/annrheumdis-2013-203296
49. Du Pan SM, Scherer A, Gabay C, et al. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis. Ann Rheum Dis 2012;71:997-9.
50. Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of biological treatment opinions after tumor necrosis factor-α inhibitor failure in rheumatoid arthritis: systemic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012;71:1303-8.
51. Méric JC, Mulleman D, Ducourau E, et al. Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. Ther Drug Monit 2011;33:411-16.
52. den Broeder AA, van der Maas A, van den Bemt B. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology 2010;49:1801-3.